Clinical Trial Update: Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating the combination of carfilzomib, romidepsin, and lenalidomide in relapsed or refractory T-cell lymphomas; trial completed with posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Lymphoma

Drugs mentioned

• Carfilzomib (carfilzomib)
• Lenalidomide (lenalidomide)
• Romidepsin (romidepsin)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: T-cell Lymphomas, Relapsed or Refractory | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-04-04